EN DE

Basma Adeem Medical company (9626) Fair Value & Analysis

Healthcare · SA · Market cap 138M SAR

BA Basma Adeem Medical company 9626 · SR
Price6.90 SAR
Fair Value6.48 SAR
Upside-6.1%
Quality67/100
Healthy Growth
Solidly profitable · 16.1% net margin
generates free cash flow
Ranks above peers (10/11)
Wide moat 70/100
Watch Basma Adeem Medical company for free, get notified when fair value or trend changes. Watch for free
Evidence: High Range 4.96 SAR – 8.00 SAR Share as image

Fair value as of: Aug 1, 2026

From 23 valuation models · updated today

Share price +10.4% over the past month.

Price vs Fair Value (8 months)

6.90 SAR 5.18 SAR Fair Value 6.48 SAR Dec 2025 Jul 2026

8‑month range 5.18 SAR – 6.90 SAR · fair‑value band 4.96 SAR – 8.00 SAR · the 6.90 SAR price screens above the 6.48 SAR fair value. As of Aug 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Basma Adeem Medical company (9626) currently trades at 6.90 SAR, while our model-based Fair Value estimate is 6.48 SAR, implying the stock looks roughly 6.1% fairly valued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Basma Adeem Medical company generated revenue of 45.5M SAR at a net margin of 16.1%. Revenue grew 44.1% year over year. It earns a return on equity of 21.4%. The balance sheet holds a net cash position of 8.3M SAR. Fundamentals as of Aug 1, 2026

Our scenario range runs from 4.96 SAR (bear case) to 8.00 SAR (bull case); at 6.90 SAR, the current price sits within that range. The share trades about 1% below its 52-week high and 33% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -19% fair-value upside, at -6%, 9626 screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 45.5M SAR
Revenue growth (YoY) +44.1%
Net margin 16.1%
Return on equity 21.4%
Free cash flow 11.4M SAR FY2025
P/E ratio 17.3
More key figures
Operating margin 19.8%
EPS (TTM) 0.4000 SAR
EPS growth (YoY) +4.5%
Net cash 8.3M SAR FY2024

Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 67/100
Profitability 59
Quality Growth 20
Cashflow 89
Fin. Strength 91
Investment 33
Low Volatility 41
Momentum 75
52W Momentum 78
Net Issuance 100

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Basma Adeem Medical company provides dental services in the Kingdom of Saudi Arabia. Its services include same day surgery; dermatology and laser; dental repair, restorations, and cosmetic dentistry; gum surgery and dental implant; root canal treatment; oral and dental health; pediatric dentistry; and maxillofacial surgery, as well as orthodontic treatment …

Full company description

Basma Adeem Medical company provides dental services in the Kingdom of Saudi Arabia. Its services include same day surgery; dermatology and laser; dental repair, restorations, and cosmetic dentistry; gum surgery and dental implant; root canal treatment; oral and dental health; pediatric dentistry; and maxillofacial surgery, as well as orthodontic treatment for dental, face, and jaw surgery. Basma Adeem Medical company was incorporated in 2012 and is headquartered in Riyadh, the Kingdom of Saudi Arabia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

Basma Adeem Medical company reported revenue of 45.5M SAR in FY2025 versus 21.9M SAR in FY2022, a compound +27.5%/yr. Reported net income was 7.3M SAR in FY2025, compounding +24.5%/yr from FY2022.

Revenue +27.5%/yr
FY22 21.9M SAR
FY23 26.5M SAR
FY24 33.9M SAR
FY25 45.5M SAR
Net income +24.5%/yr
FY22 3.8M SAR
FY23 4.9M SAR
FY24 6.3M SAR
FY25 7.3M SAR

Is 9626 fairly valued? → Check now

Share or link this analysis
📋 Free embed code + live data for your site

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Basma Adeem Medical company Fair Value". https://www.fairvalue-calculator.com/stock/9626.SR

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 25 / 21
FUTURE 100 / 25
PAST 85 / 29
HEALTH 0 / 90
DIVIDEND 0 / 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$100.00 R$25.67 -74%
Fresenius SE FRE €39.54 €31.98 -19%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.76 SGD 1.28 SGD -54%
Tenet Healthcare Corporation THC $178.75 $300.86 +68%
Rede D'Or São Luiz S.A RDOR3 R$32.50 R$46.04 +42%
DaVita Inc DVAI34 R$1,002 R$1,038 +4%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,305 ₹2,546 -69%
Fresenius Medical Care AG FMSC34 R$112.00 R$164.60 +47%
Aier Eye Hospital Group 300015 ¥8.54 ¥6.73 -21%

Compare Basma Adeem Medical company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Basma Adeem Medical company (9626) overvalued or undervalued?
As of Aug 1, 2026, our model estimates a fair value of 6.48 SAR versus a price of 6.90 SAR, about −6% (fairly valued).
What is the fair value of 9626?
Our model-based fair value for Basma Adeem Medical company is 6.48 SAR (as of Aug 1, 2026), built from audited fundamentals. The current price is 6.90 SAR.
What is the quality score of 9626?
Basma Adeem Medical company has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Basma Adeem Medical company (9626)?
Basma Adeem Medical company reported trailing-twelve-month revenue of about 45.5M SAR (latest available figure, as of Aug 1, 2026).
What is the net profit margin of 9626?
The net profit margin of Basma Adeem Medical company is about 16.1%, meaning it keeps roughly 16.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Basma Adeem Medical company and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.